John Ruedy, MD; Martin Schechter, MD; Julio S. G. Montaner, MD
Since it was originally described in 1981, the acquired immunodeficiency syndrome (AIDS) has been a complex therapeutic challenge. In 1983, the discovery of human immunodeficiency virus type 1 (HIV) as the causative agent of AIDS opened the door for the rational development of specific therapeutic agents. To date, only one such agent, zidovudine (also known as azidothymidine, or AZT) has been definitively shown to alter the usually rapidly fatal course of AIDS (1, 2). Results of a number of recently concluded trials, some of them still unpublished, in patients at earlier stages of HIV infection necessitate a reassessment of our
Learn more about subscription options.
Register Now for a free account.
Ruedy J, Schechter M, Montaner JSG. Zidovudine for Early Human Immunodeficiency Virus (HIV) Infection: Who, When, and How?. Ann Intern Med. 1990;112:721–723. doi: 10.7326/0003-4819-112-10-721
Download citation file:
Published: Ann Intern Med. 1990;112(10):721-723.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only